Faster global financial news!
Fosun Pharma: Luwomeitinib Tablets Receive Approval for Clinical Trials
Fosun Pharma announced that its controlling subsidiary, Shanghai Fosun Pharma Industrial Development Co., Ltd., has received approval from the National Medical Products Administration (NMPA) to conduct clinical trials of Fumining in combination with anlotinib for patients with advanced non-small cell lung cancer harboring murine sarcoma virus (MSV) oncogene mutations. Fosun Pharma Industrial plans to conduct Phase II clinical trials of the drug in China once conditions are met.
No AI analysis yet. Tap the "AI Analysis" button above to generate one now.
Disclaimer: This content reflects the author's personal views only and does not constitute investment advice.
24H Trending
-
1
CNBC: Colom leads by 2,607 votes in Mississippi Senate race, race uncalled
-
2
RTHK: U.S. stocks closed lower on Tuesday, with the Dow down 0.3% and the Nasdaq down 0.7%.
-
3
Al Jazeera: Meta Expands AI Age Verification, Rolling Out Globally on Instagram while Threads Rollout Remains Planned
-
4
Nikkei Stock Average flat at 60,451.02 as bank and pharma gains offset tech and machinery losses
-
5
Hong Kong and mainland Chinese stocks opened lower, weighed down by higher-than-expected US inflation and escalating interest rate hike expectations.
-
6
Financial Times: Anthropic's underwriting banks prepare to boost IPO valuation to at least $1.5 trillion
-
7
Al Jazeera: UKMTO receives report of incident involving oil tanker in Strait of Hormuz, details unclear
-
8
Hong Kong's Insurance Authority (IA) has prohibited Lim Ka Kit from engaging in insurance intermediary business for nine months.
-
9
CNBC: CoreWeave Raises Full-Year Revenue Guidance to $13B–$13.3B, Widens Net Loss in Q3
-
10
Where to Buy and Sell Flow (FLOW)? Latest 2026 Buying Channels and Ecosystem Analysis
Markets Today
Recommended Reading
Hot Topics
Svmuu focuses on blockchain industry trends and cutting-edge cryptocurrency news, while also covering real-time market data and in-depth analysis of the Hong Kong, U.S., and foreign exchange markets. Here, you can not only access professional 24/7 news updates and accurate market data, but also utilize practical investment tools to help you capitalize on opportunities in both digital assets and traditional financial markets. Whether you are a blockchain enthusiast or an investor in Hong Kong, U.S., or foreign exchange markets, we provide efficient and timely information services to empower your investment decisions.
- User Agreement
- Privacy Policy
- Contact Us
- Business Partnerships
- Disclaimer
- Content Statement
- About Us
- Sitemap
Coming Soon!
